Considerations for managing chronic obstructive pulmonary disease in the elderly

Clinical Interventions in Aging

Volumn 9, Issue , 2013, Pages 23-30

  Taffet, George E ^a   Donohue, James F ^b   Altman, Pablo R ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Medical Affairs   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cognition; Comorbidities; Device; Disability; Inhaler; Maintenance therapy

Indexed keywords

ARFORMOTEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; LEVALBUTEROL; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; METERED DOSE INHALER; MINI MENTAL STATE EXAMINATION; NEBULIZER; PATIENT SELECTION; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPIROMETRY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COGNITION; COMORBIDITIES; DEVICE; DISABILITY; INHALER; MAINTENANCE THERAPY;

ADMINISTRATION, INHALATION; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM;

EID: 84890352930     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S52999     Document Type: Review

References (44)

1. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. NCHS Data Brief. 2011; 63: 1-8.
2. Centers for Disease Control and Prevention, National Center for Health Statistics. Data brief 63: chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. Available from: http://www. cdc. gov/nchs/data/databriefs/db63_tables. pdf#2. Accessed August 8, 2013.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. Available from: http://www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html. Accessed August 30, 2013.
4. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008; 63(9): 831-838.
5. Janssens JP. Aging of the respiratory system: impact on pulmonary function tests and adaptation to exertion. Clin Chest Med. 2005; 26(3): 469-vii.
6. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006; 1(3): 253-260.
7. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159(1): 179-187.
8. Pezzoli L, Giardini G, Consonni S, et al. Quality of spirometric performance in older people. Age Ageing. 2003; 32(1): 43-46.
9. Allen SC, Baxter M. A comparison of four tests of cognition as predictors of inability to perform spirometry in old age. Age Ageing. 2009; 38(5): 537-541.
10. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc. 1992; 40(9): 922-935.
11. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011; 155(3): 179-191.
12. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001; 5(26): 1-149.
13. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011; 68(13): 1221-1232.
14. Zarowitz BJ, O'Shea T. Chronic obstructive pulmonary disease: prevalence, characteristics, and pharmacologic treatment in nursing home residents with cognitive impairment. J Managed Care Pharm. 2012; 18(8): 598-606.
15. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008; 3(3): 371-384.
16. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005; 128(5): 3198-3204.
17. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep. 2005; 54(25): 625-628.
18. Gentil L, Vasiliadis HM, Preville M, Bosse C, Berbiche D. Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc. 2012; 60(12): 2297-2301.
19. Bosley CM, Corden ZM, Rees PJ, Cochrane GM. Psychological factors associated with use of home nebulized therapy for COPD. Eur Respir J. 1996; 9(11): 2346-2350.
20. Allen SC. Competence thresholds for the use of inhalers in people with dementia. Age Ageing. 1997; 26(2): 83-86.
21. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010; 35(4): 913-922.
22. Villeneuve S, Pepin V, Rahayel S, et al. Mild cognitive impairment in moderate to severe COPD: a preliminary study. Chest. 2012; 142(6): 1516-1523.
23. Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF. Characteristics predicting incorrect metered-dose inhaler technique in older subjects. Arch Intern Med. 1996; 156(9): 984-988.
24. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009; 122(4): 348-355.
25. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir Med. 2005; 99(1): 97-102.
26. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002; 19(2): 246-251.
27. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008; 75(1): 18-25.
28. Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev. 2005; 14(96): 117-122.
29. Hess DR. Metered-dose inhalers and dry powder inhalers in aerosol therapy. Respir Care. 2005; 50(10): 1376-1383.
30. Todd MA, Baskett JJ, Richmond DE. Inhaler devices and the elderly. N Z Med J. 1990; 103(883): 43-46.
31. Yawn BP, Colice GL, Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2012: 7495-7502.
32. Gray SL, Nance AC, Williams DM, Pulliam CC. Assessment of interrater and intrarater reliability in the evaluation of metered dose inhaler technique. Chest. 1994; 105(3): 710-714.
33. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005; 50(10): 1304-1312.
34. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008; 102(4): 593-604.
35. Broeders ME, Vincken W, Corbetta L. The ADMIT series-Issues in Inhalation Therapy. 7. Ways to improve pharmacological management of COPD: the importance of inhaler choice and inhalation technique. Prim Care Respir J. 2011; 20(3): 338-343.
36. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008; 31(1): 78-83.
37. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007; 101(11): 2395-2401.
38. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(®) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013; 26(3): 174-179.
39. Filuk R. Delivery system selection: clinical considerations. Am Health Drug Benefits. 2008; 1(Suppl 8): 13-17.
40. Rau JL. Practical problems with aerosol therapy in COPD. Respir Care. 2006; 51(2): 158-172.
41. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011; 377(9770): 1032-1045.
42. Bowles SK, Sketris I, Kephart G. Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded Seniors' Pharmacare Program in Nova Scotia, Canada. Am J Geriatr Pharmacother. 2007; 5(2): 120-128.
43. Rees J. ABC of asthma. Methods of delivering drugs. BMJ. 2005; 331(7515): 504-506.
44. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127(1): 335-371.